Key result
NCF4 rs1883112 genotype status was significantly associated with increased risk of doxorubicin cardiotoxicity (OR 10.80; 95% CI 1.69-68.98; P=0.01) in children with acute lymphoblastic leukemia.
Why the study?
Data documenting the impact of genetic polymorphisms on anthracycline-related cardiotoxicity in pediatric cancer patients from Latin American countries are scarce.
Do NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 genetic polymorphisms modify the risk of anthracycline-induced cardiotoxicity in children with acute lymphoblastic leukemia?
Observational (n=67)
No
Do NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 genetic polymorphisms modify the risk of anthracycline-induced cardiotoxicity in children with acute lymphoblastic leukemia?
Odds Ratio: 10.8 (95% CI 1.69–68.98)
p-value: p=0.01
Specific genetic polymorphisms (NCF4 rs1883112 and CBR3 rs1056892) are associated with an increased risk of anthracycline-induced cardiotoxicity in Mexican children with acute lymphoblastic leukemia, while ABCC1 rs3743527 may be protective.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for NCF4/CBR3 variants in Latin American pediatric oncology; prospective validation required before any clinical application.
Gándara‐Mireles et al. (2021) conducted an observational in acute lymphoblastic leukemia (n=67). NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 genetic polymorphisms vs. Reference genotypes was evaluated on doxorubicin cardiotoxicity (OR 10.80, 95% CI 1.69-68.98, p=0.01). NCF4 rs1883112 genotype status was significantly associated with increased risk of doxorubicin cardiotoxicity (OR 10.80; 95% CI 1.69-68.98; P=0.01) in children with acute lymphoblastic leukemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: